在之前接受BCMA向治疗后,多发性骨髓瘤患者接受ide-cel的现实世界经验

Christopher J Ferreri1, Michelle A T Hildebrandt1, Hamza Hashmi2

  • 1The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Blood cancer journal
|August 9, 2023
PubMed
概括

患有复发性多发性骨髓瘤的患者接受了顺序的B细胞成熟抗原向治疗 (BCMA-TT),其反应率较低,无进展存活时间较短,与idecabtagene vicleucel. 然而,之前接受CAR T细胞治疗的患者获得了最好的结果.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K